LAB Earnings & Financial Statements
Standard BioTools Inc.
$0.64
+$0.01(+1.27%)
36
Overall
60
Value
14
Tech
36
Quality
Market Cap
$249.42M
Volume
4.68K
52W Range
$0.63 - $1.72
Target Price
$1.35
LAB earnings and financial statements: Standard BioTools Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LAB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $85.33M | $91.01M | $106.34M | $97.95M | $130.58M |
| Cost of revenue | $42.79M | $46.13M | $55.89M | $60.90M | $61.21M |
| Operating income | -$110.25M | -$127.48M | -$76.60M | -$116.20M | -$67.46M |
| EBITDA | -$85.72M | -$73.54M | -$59.02M | -$176.24M | -$44.27M |
| Net income | -$74.90M | -$138.88M | -$74.66M | -$190.10M | -$59.24M |
| EPS (diluted) | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $567.75M | $612.35M | $323.07M | $390.31M | $275.21M |
| Total liabilities | $143.46M | $140.62M | $159.87M | $160.52M | $180.62M |
| Shareholders’ equity | $424.29M | $471.72M | -$148.05M | -$81.47M | $94.60M |
| Cash and equivalents | $120.86M | $166.73M | $51.70M | $81.31M | $28.45M |
| Long-term debt | $25.34M | $25.89M | $34.36M | $96.89M | $101.76M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$74.34M | -$143.45M | -$43.29M | -$89.37M | -$44.06M |
| Capital expenditure | -$8.30M | -$8.36M | -$2.83M | -$3.83M | -$13.26M |
| Free cash flow | -$82.65M | -$151.81M | -$46.12M | -$93.19M | -$57.33M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LAB | $0.64 | +1.3% | 4.68K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |